Health — 28 March 2013

Biogen MS drugBy Richard Lenti

The Food and Drug Administration has approved a new oral drug for the treatment of multiple sclerosis (MS).

Manufactured by the Cambridge, Massachusetts-based Biogen Idec (NASDAQ: BIIB), twice-a-day capsules of dimethyl fumarate will be sold under the brand name Tecfidera and should be available within the coming weeks. Biogen has not disclosed the price of the drug, but like other MS medications, monthly treatments are expected to cost tens of thousands of dollars.

Read more at National Pain Report.


About Author

Richard Lenti

Richard Lenti has worked as a news writer for the last 20 years at various television stations in Los Angeles. He is a Golden Mike winner and a graduate of California State University, Fresno. With roots in print journalism, Richard is excited to be “published” once again; having people read his work as opposed to having it read to them. As a freelance writer his work has appeared in the Easy Reader, L.A. Jazz Scene, Irrigation and Green Industry, and the KCAL 9 Online website.

(0) Readers Comments

Comments are closed.